二级医疗中心丁型肝炎病毒感染的长期研究:病毒血症对肝脏相关结局的影响
瑞典全国性队列回顾性研究337例乙肝合并丁肝抗体阳性患者,其中233例基线HDV RNA阳性、91例无病毒血症,平均随访6.5年。HDV病毒血症者肝脏相关事件风险为无病毒血症者的3.8倍,肝细胞癌风险为2.6倍但无统计学意义。基线无肝硬化且HDV病毒血症者5年和10年无肝硬化或肝脏相关事件累积风险分别为81.9%和64.0%。
要点
- HDV RNA病毒血症与肝脏相关事件风险升高3.8倍相关。
- 基线无肝硬化的HDV病毒血症者10年无事件累积风险为64.0%。
- 二级医疗中心HDV病毒血症者预后较三级中心既往估计更良性。
核心结论
- HDV RNA病毒血症与肝脏相关结局风险升高3.8倍相关。
- 基线无肝硬化的HDV病毒血症者预后仍较差,但较三级中心既往估计更良性。
研究设计与样本
- 瑞典全国性多中心回顾性队列研究,纳入337例抗-HDV阳性患者,其中233例有HDV病毒血症、91例无病毒血症。
- 平均随访6.5年(范围0.5-33.1年),采用Cox回归分析评估肝脏相关事件长期风险。
主要发现
- HDV病毒血症者肝脏相关事件风险为无病毒血症者的3.8倍,肝细胞癌风险为2.6倍但无统计学意义。
- 基线无肝硬化的HDV病毒血症者5年和10年无肝硬化或肝脏相关事件累积风险分别为81.9%和64.0%。
- 对应发病率为0.04例/人年。
临床怎么用
- 对乙肝合并丁肝患者应检测HDV RNA以评估病毒血症状态和肝脏相关事件风险。
- 基线无肝硬化的HDV病毒血症者仍需长期监测肝脏相关事件。
局限性
- 回顾性研究设计。
- 来自二级医疗中心,可能存在转诊偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Hepatitis delta virus (HDV) infection is associated with fast progression to liver cirrhosis and liver complications. Previous studies have, however, been mainly from tertiary care centers, with risk for referral bias toward patients with worse outcomes. Furthermore, the impact of HDV viremia per se on liver-related outcomes is not really known outside the human immunodeficiency virus co-infection setting. We have therefore evaluated the long-term impact of HDV viremia on liver-related outcomes in a nationwide cohort of patients with hepatitis B and D co-infection, cared for at secondary care centers in Sweden. APPROACH AND RESULTS: In total, 337 patients with anti-HDV positivity, including 233 patients with HDV RNA viremia and 91 without HDV viremia at baseline, were retrospectively studied, with a mean follow-up of 6.5 years (range, 0.5-33.1). The long-term risks for liver-related events (i.e., hepatocellular carcinoma [HCC], hepatic decompensation, or liver-related death/transplantation) were assessed, using Cox regression analysis. The risk for liver-related events and HCC was 3.8-fold and 2.6-fold higher, respectively, in patients with HDV viremia compared with those without viremia, although the latter was not statistically significant. Among patients with HDV viremia with no baseline cirrhosis, the cumulative risk of being free of liver cirrhosis or liver-related events was 81.9% and 64.0% after 5 and 10 years of follow-up, respectively. This corresponds to an incidence rate of 0.04 cases per person-year. CONCLUSIONS: HDV RNA viremia is associated with a 3.8-fold higher risk for liver-related outcomes. The prognosis was rather poor for patients with HDV viremia without cirrhosis at baseline, but it was nevertheless more benign than previous estimates from tertiary centers. Our findings may be of importance when making decisions about treatment and evaluating potential outcomes of upcoming antivirals against HDV.
引用
- Kamal H, Westman G, Falconer K, et al. Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. Hepatology. 2020. PMID: 32145073. doi:10.1002/hep.31214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。